McKesson (MCK) Restructuring Reserve Settled Without Cash2 — Quarterly & Annual

Screener

Restructuring Reserve Settled Without Cash2 at other companies

Carpenter TechnologyCRS

$0—

MBC

MasterBrandMBC

$4.1M+583%

The Honest CompanyHNST

$655K—

Crown CastleCCI

$0-100%

ResMedRMD

$0-100%

West Pharmaceutical ServicesWST

$1M+25.0%

Segments

By segment

Prescription Technology Solutions$40M—

North American Pharmaceutical$1M—

Medical-Surgical Solutions$0—

Oncology & Multispecialty$0-100%

Other financials

Income statement

Revenue$105.38B+7.7%

Gross profit$3.7B+12.4%

Operating income$1.3B+27.3%

Net income$614.0M-21.7%

EPS (diluted)$5.15-17.6%

Balance sheet

Cash & equivalents$5.3B+95.9%

Total debt$13.0B+15.7%

Total equity-$4.2B-116%

Total assets$88.3B+8.6%

Cash flow

Operating cash flow-$220.0M+76.0%

CapEx$112.0M+0.9%

Free cash flow-$332.0M+67.7%

Valuation

Market cap$101.59B+15.6%

Enterprise value$109.31B+13.4%

P/E22.1×-5.7×

P/S0.3×0.0×

Profitability

Gross margin3.6%+0.1pp

Operating margin1.6%+0.4pp

Net margin1.1%+0.3pp

FCF margin1.6%0.0pp

Returns & leverage

Return on equity36%—

Debt / equity2×—

Current ratio0.9×0.0×